Aurora Cannabis Sets Course for Growth at Global Investment Conference in NYC

Aurora Cannabis at H.C. Wainwright Global Investment Conference

Aurora Cannabis Inc., recognized as a leader in the medical cannabis industry, is gearing up for the H.C. Wainwright 27th Annual Global Investment Conference. This event, held in New York City from September 8-10, 2025, will serve as an important platform for the company's leadership, particularly Chief Financial Officer Simona King, to engage directly with investors.

The three-day conference is set to feature one-on-one meetings, allowing investors an opportunity to discuss strategies and outlooks directly with Aurora’s management. Simona King has prepared an insightful presentation that outlines Aurora's strategic investments and the company's roadmap for sustaining long-term shareholder value amidst a rapidly evolving industry landscape.

The medical cannabis sector has seen remarkable growth, and Aurora has positioned itself at the forefront. Operating across Canada, Europe, Australia, and New Zealand, the company aims to revolutionize the accessibility and application of cannabis in medical settings. Aurora’s diverse product portfolio underscores its commitment to not only medical but also consumer markets, with brands such as MedReleaf and CanniMed leading the way in medical cannabis and Drift and Greybeard catering to the recreational market.

During her presentation at the conference, Simona will delve into the innovative steps Aurora is taking to navigate the complexities of the medical cannabis industry. Participants can access this presentation via a live stream, and a recording will be available for viewing afterward, allowing a wider audience to benefit from the insights shared.

Aurora’s headquarters in Edmonton, Alberta, serves as a hub for the company’s operations, underscoring its heritage as a Canadian-based pioneer in this space. The company also maintains a significant agricultural operation through its controlling interest in Bevo Farms Ltd., which is recognized as North America's leading supplier of propagated plants. This vertical integration not only fortifies Aurora’s product offerings but also enhances its supply chain management, a critical aspect in ensuring high-quality product delivery.

Investors are keenly watching Aurora due to its potential for market expansion and innovative product development. The cannabis industry is notorious for its volatility, influenced by regulatory changes and shifting consumer attitudes. Consequently, Aurora's strategic focus on both the medical cannabis sector, through research and high-quality products, as well as an engaging recreational portfolio, positions it uniquely in the marketplace.

The conference's forward-looking information segment reflects Aurora's proactive stance on maintaining investor relationships while addressing the inherent risks in the cannabis sector. The climate of uncertainties around legislation and market demand can impact operational performance; hence, Aurora’s transparency about its growth strategies is crucial to building investor confidence.

As Aurora continues to evolve, it also engages in various outreach initiatives via social channels and investor segments to keep shareholders informed of their strategies and progress. By fostering an open dialogue with investors, Aurora aims to build a robust support network that emphasizes shared goals and mutual growth.

Overall, Aurora Cannabis Inc.'s participation in the H.C. Wainwright conference exemplifies its ongoing commitment to innovation, transparency, and the pursuit of excellence in the medical cannabis landscape. As the company lays out its vision for future growth, stakeholders will be keen to observe how these strategies unfold in an ever-changing market environment.